AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%

AbCellera Biologics Inc.

2022-Q3 EPS reported $0.60 revenue$463,879,000

Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.
Bebtelovimab royalties contributed $93.3M; research fees $7.5M, milestones $0.4M, licensing $0.2M.
Cumulative program starts reached 92, up 33% from 69 in Q3 2021; partners increased to 38.
Cash, cash equivalents and marketable securities stood at $868M.
R&D expenses $26.6M (up 52% YoY) reflecting continued investment in discovery engine.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbCellera Biologics Inc. reported Q3 2022 results: revenue $101.4 million, net income $26.6 million, EPS $0.09 per share (basic) and $0.08 per share (diluted).

Period: Q3 2022
Revenue: $101.4 million
Net income: $26.6 million
EPS: $0.09 per share (basic) and $0.08 per share (diluted)
Result: reported results

Exact text from the filing

Total revenue of $101 million, compared to $6 million in Q3 2021 • Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 • Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-037057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.